trending Market Intelligence /marketintelligence/en/news-insights/trending/kXhhJ0DI0WoK2EfrzEb2pQ2 content esgSubNav
In This List

AbbVie arthritis drug meets endpoint in phase 3 trial

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


AbbVie arthritis drug meets endpoint in phase 3 trial

AbbVie Inc. said its investigational drug upadacitinib met its primary endpoint in a phase 3 trial.

The company was evaluating the drug in patients with moderate to severe rheumatoid arthritis who did not adequately respond to prior therapy.

More than half the patients achieved a 20% improvement at week 12 of the trial, compared to 36% of patients who received placebo. Low disease activity was achieved by 48% of patients, compared to the 17% on placebo.

The drug is also being investigated to treat Crohn's disease, ulcerative colitis and atopic dermatitis.

Phase 3 trials of upadacitinib in psoriatic arthritis are also ongoing.